

GLOBAL MARKETS FOR DRUG-DEVICE COMBINATIONS



PHM045D
January 2015

Kevin Gainer
Project Analyst

ISBN: 1-62296-025-4



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
THE IMPORTANCE OF THIS STUDY	2
INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
SCOPE OF THE INDUSTRY	7
DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET	7
<i>SUMMARY TABLE SALES OF DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ BILLIONS)</i>	8
<i>SUMMARY FIGURE SALES OF DRUG-DEVICE COMBINATION PRODUCTS, 2013-2019 (\$ BILLIONS)</i>	8
TECHNOLOGY AND PATENT ACTIVITY	9
THE CENTRAL ROLE OF THE FDA	10
CHAPTER 3 CURRENT STATUS OF THE DRUG-DEVICE COMBINATION INDUSTRY	12
OVERVIEW	12
ROLE OF THE FDA	12
<i>TABLE 1 EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS</i>	14
OFFICE OF COMBINATION PRODUCTS ORGANIZATIONAL STRUCTURE	14
HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE	15
EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS	15
FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS	16
<i>TABLE 2 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS</i>	17
THE RELATION BETWEEN NANOTECHNOLOGY AND COMBINATION PRODUCTS	17
<i>TABLE 3 COMPANIES INVOLVED IN DRUG RELATED NANOTECHNOLOGY R&D OR MANUFACTURING</i>	18
FDA TRENDS IN REVIEWING COMBINATION PRODUCTS	20
<i>TABLE 4 TRENDS IN COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-2012 (NO. OF PRODUCT SUBMISSIONS)</i>	21
<i>TABLE 5 FDA COMBINATION PRODUCT CATEGORIES, FY2010-FY2012</i>	22
CHAPTER 4 REGULATORY PROCESS AND ISSUES	25
REGULATORY FUNDING	25
OVERSEAS AND WORLD REGULATION	25
FDA OFFICE OF COMBINATION PRODUCTS	26
SCOPE OF FDA ACTION	26
TREATMENT OF DEVICES	26
CLASS I DEVICES	27
CLASS II DEVICES	27

TOPIC	PAGE NO.
CLASS III DEVICES	27
CURRENT STATUS OF FDA AND NANOTECHNOLOGY INITIATIVES	28
FDA NANOTECH PRODUCT APPROVALS	29
OTHER RELEVANT HEALTH OR REGULATORY AGENCIES	30
TYPICAL REGULATORY MILESTONES IN COMBINATION PRODUCT APPROVALS	30
CLINICAL TRIALS	31
CHAPTER 5 NANOTECH COMBINATION PRODUCTS	33
OVERVIEW	33
REPRESENTATIVE COMPANIES	33
<i>TABLE 6 COMPANIES WITH SIGNIFICANT SPECIALIZATION IN NANOMEDICINE, 2014 (\$ MILLIONS)</i>	34
NATIONAL NANOTECHNOLOGY INITIATIVE	35
NANOTECH REGULATORY ENVIRONMENT	36
COMBINATION NANOTECHNOLOGY PRODUCT RESEARCH	38
PRODUCTS	38
PERMANENT MRI CONTRAST AGENTS	39
NANOPARTICLE IMAGING AGENTS	40
NANOPARTICLE TO SEQUENCE DRUG DELIVERY	40
VACCINE DELIVERY VIA NANOPARTICLES	41
NANODIAMOND DRUG DEVICES FOR CANCER TREATMENT	41
WAX NANOPARTICLES ENHANCE IMMUNE RESPONSE	42
BRAIN-PENETRATING NANOPARTICLES	43
COMBINED POLYETHYLENE GLYCOL-HYDROPHILIC CARBON CLUSTERS	43
NANO-SYRINGES	44
NANOPARTICLES PROTECT AGAINST SEXUALLY TRANSMITTED INFECTIONS	44
<i>NANOTECHNOLOGY-MAGNETISM COMBINATION IN TINY IMPLANTABLE DEVICE FOR DRUG DELIVERY</i>	45
IMPLANTS USING CONDUCTING POLYMER NANOTUBES	45
CALCIUM PHOSPHATE NANOPARTICLES FOR DRUG DELIVERY	46
NANO-SCALE DELIVERY OPTIMIZES CHEMOTHERAPY REGIMES	47
DRUG INFUSED NANOPARTICLES	48
ENCAPSULATION OF DRUG TREATMENTS IN NANOPARTICLES	49
SILICON NANOWIRES FOR DRUG DELIVERY	50
MINUTE ANTIBACTERIAL PARTICLES DESTROY DRUG-RESISTANT GERMS	51
BIODEGRADABLE CATIONIC CORE-SHELL NANOPARTICLES FOR CO-DELIVERY OF DRUGS AND GENES	52
STIMULI-SENSITIVE CORE-SHELL NANOPARTICLES FOR CANCER THERAPY	52
POLYMER-BASED NON-VIRAL GENE CARRIERS	52
MAGNETICALLY TARGETED NANOPARTICLES TO TREAT PERIPHERAL ARTERY DISEASE	53
POTENTIAL HEALTH EFFECTS: IMPACT ON NANO INDUSTRY	53
<i>TABLE 7 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	55
CHAPTER 6 DRUG-ELUTING CORONARY STENTS	57
OVERVIEW	57
MECHANISM OF ACTION	58

TOPIC	PAGE NO.
CLINICAL TRIALS	58
DEFINITION AND SIZE OF TARGET MARKET	59
<i>TABLE 8 MARKETS FOR CORONARY STENTS, THROUGH 2019 (\$ BILLIONS)</i>	60
FDA REGULATORY ROLE WITH REGARD TO STENTS	60
FDA STENT APPROVAL HISTORY	61
STENT APPROVALS IN 2011-2013	63
Medtronic	63
Boston Scientific	63
Medtronic	64
Abbott	64
<i>TABLE 9 STENT APPROVAL ACTIVITY AT FDA, 2012-2013</i>	64
PRINCIPAL DRUG ELUTED STENT PRODUCERS	65
STENT DESIGN	65
PRODUCT LINES	66
<i>TABLE 10 EXAMPLES OF STENTS APPROVED FOR CLINICAL USE</i>	69
STENT PRODUCT INNOVATIONS AND R&D: BIOABSORBABLE STENTS	69
COMPETITIVE SITUATION	69
<i>TABLE 11 RECENT BIOABSORBABLE STENT PATENTS, 2009-2014</i>	70
R&D STATUS	71
BIODEGRADABLE COATINGS	72
MARKETS FOR STENT RELATED TECHNOLOGIES	72
LIPISCAN CORONARY IMAGING SYSTEM	72
CHAPTER 7 PHOTODYNAMIC THERAPIES	76
OVERVIEW	76
TREATMENT LIMITATIONS	76
TECHNOLOGY HISTORY	77
FIRST GENERATION DEVELOPMENTS	78
SECOND GENERATION PDT SENSITIZERS	78
PDT MARKETS FOR CANCER	79
PDT MARKETS FOR MACULAR DEGENERATION	79
PDT MARKETS FOR PSORIASIS	80
TYPES OF UVB THERAPY FOR PSORIASIS	80
PUVA PHOTOCHEMOTHERAPY	81
TARGETED PHOTOTHERAPY (EXCIMER LASER)	81
OTHER MEDICAL APPLICATIONS	81
OPTOGENETICS	82
PDT MARKET GROWTH DRIVERS	83
EXAMPLES OF PDT PRODUCTS	83
VISUDYNE (NOVARTIS)	84
LEVULAN	84
PHOTOFRIN (PORFIMER SODIUM)	84
APTOCINE	85
VISONAC	85
CEVIRA	85
LUMACAN	86
RESEARCH AND DEVELOPMENT	86

TOPIC	PAGE NO.
INTERVENTIONAL CARDIOLOGY	86
Cardiac Ablation	86
DERMATOLOGY	87
AUTOIMMUNE DISEASES	87
CANCER	88
Mesothelioma	88
Prostate Cancer	89
ANTIMICROBIAL APPLICATIONS	89
EQUIPMENT PRODUCERS	90
<i>TABLE 12 PHOTODYNAMIC THERAPY MARKETS, THROUGH 2019 (\$ BILLIONS)</i>	90
CHAPTER 8 ANTIMICROBIALS AND OTHER MEDICAL DEVICE COATINGS	92
OVERVIEW: REGULATORY TREATMENT	92
DRIVING FORCE IN DEVELOPMENT OF ANTIMICROBIALS	92
MARKET CONTEXT AND PREVALENCE OF INFECTIONS	94
EXAMPLES OF USE	95
CLINICAL TRIALS WITH COPPER AS AN ANTIMICROBIAL	96
RELATED PRODUCTS	96
TRENDS IN FDA APPLICATIONS FOR ANTIMICROBIALS	97
<i>TABLE 13 REVENUES ATTRIBUTABLE TO ANTIMICROBIALS THROUGH 2019 (\$ BILLIONS)</i>	97
ANTIMICROBIAL AND OTHER MEDICAL DEVICE COATINGS	97
MARKET CATEGORIES FOR MEDICAL DEVICE COATINGS IN COMBINATION PRODUCTS	98
<i>TABLE 14 REVENUES ATTRIBUTABLE TO MEDICAL DEVICE COATINGS, THROUGH 2019 (\$ BILLIONS)</i>	99
EXAMPLE PRODUCTS	99
<i>TABLE 15 MEDICAL DEVICE PRODUCTS INCORPORATING AN ANTIMICROBIAL FUNCTION</i>	99
CHAPTER 9 ANTIMICROBIAL CATHETERS	102
MARKET OVERVIEW	102
CLINICAL TRIALS	102
<i>TABLE 16 CURRENT FDA APPROVED CLINICAL TRIALS FOCUSED ON NEW ANTIMICROBIAL CATHETER CONCEPTS (AS OF JULY 2014)</i>	102
APPLICATIONS	104
MARKET SIZE	105
<i>TABLE 17 PROJECTED CATHETER MARKET BY PRODUCT TYPE, INCLUDING ANTIMICROBIAL PRODUCTS, THROUGH 2019 (\$ BILLIONS)</i>	105
CATHETER INNOVATIONS	106
ANTIMICROBIAL CATHETER CONCEPTS	106
SMART CATHETER CONCEPTS	107
SELENIUM NANOPARTICLES ON CATHETERS AND IMPLANTS	108
EXAMPLE PRODUCTS	109
5-FLUOROURACIL-COATED CENTRAL VENOUS CATHETER	109
ZURAGEN	109
DRUG - DEVICE COMBINATION CATHETER LOCK/FLUSH SOLUTIONS	110
R&D INITIATIVES	111
DIALYSIS CATHETERS	111

TOPIC	PAGE NO.
URINARY CATHETERS	112
OTHER DELIVERY TECHNIQUES	112
CHAPTER 10 DRUG-ELUTING BEADS	115
OVERVIEW	115
EXAMPLE OF THERAPY	115
COMPANY ACTIVITY	115
BEAD APPLICATIONS IN ORTHOPEDICS	117
BEAD APPLICATIONS IN STROKE	118
BEAD APPLICATIONS IN ALLERGY AND ASTHMA ATTACKS	118
RECENT FDA APPROVALS	119
RECENT OVERSEAS APPROVALS FOR CLINICAL TRIALS	119
CLINICAL TRIALS	120
<i>TABLE 18 CURRENT CLINICAL TRIALS INVOLVING DRUG-ELUTING BEADS</i>	121
R&D AND OTHER NOVEL APPLICATIONS OF BEADS	122
USING FLUORESCENT SILICA BEADS TO DETECT MALIGNANT CERVICAL CELLS	122
ANTIBODY COATED MAGNETIC BEADS TO COMBAT INFECTION	123
FUMAGILLIN NANOPARTICLES	124
POLYETHYLENE-GLYCOL (PEG) COATED NANOPARTICLES	125
CONTROLLED DELIVERY OF TUMOR-KILLER DRUGS	126
RADIATION AND IMMUNOTHERAPY COMBINATIONS	127
POLYMERIC MICROCAPSULES	127
OHIO STATE UNIVERSITY RESEARCH	127
TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY	128
<i>TABLE 19 R & D AND REVENUES ATTRIBUTABLE TO DRUG-ELUTED BEADS, THROUGH 2019 (\$ MILLIONS)</i>	129
CHAPTER 11 BONE CEMENTS INCLUDING ANTIBIOTIC	131
GENERAL APPLICATIONS	131
ANTIBIOTIC APPLICATIONS	131
EARLY HISTORY	132
APPLICATIONS	132
MARKET SIZE	133
<i>TABLE 20 ANNUAL SALES OF BONE CEMENTS, INCLUDING COMBINATION PRODUCT ANTIBIOTIC BONE CEMENTS, THROUGH 2019 (\$ MILLIONS)</i>	133
COMPOSITION	133
NEW TECHNOLOGIES	134
EXAMPLE PRODUCTS	134
RELATED PRODUCTS: TYPES OF CERAMICS	135
BIOGRAN	136
BIO-OSS	136
BONESOURCE	136
CALCIGEN S	137
CEMENTS IN DENTAL APPLICATIONS: GLASS IONOMER CEMENTS	137
CHAPTER 12 BONE GRAFT SUBSTITUTES	140
OVERALL SIZE OF BONE GRAFT BUSINESS	140

TOPIC	PAGE NO.
<i>TABLE 21 PRINCIPAL COMPANIES IN THE BONE GRAFT BUSINESS</i>	140
RECENT DEVELOPMENTS	140
OVERVIEW OF APPLICATIONS	141
BONE GRAFT SUBSTITUTES	142
<i>TABLE 22 PATENT ACTIVITY IN BONE GRAFT SUBSTITUTES FROM AUGUST 2010 TO JULY 2014</i>	142
INFUSE	144
AUGMENT	144
CARRIGEN POROUS BONE SUBSTITUTE MATERIAL	144
ALLOGRAFT TISSUE	145
OTHER OSTEOCONDUCTIVE BONE-GRAFT SUBSTITUTES	146
HYDROGELS AND NANOTUBES IN BONE GRAFTING	146
Hydrogel Bone Void Filler	148
Amphiphilic Peptides and Hydrogel Matrices Thereof for Bone Repair	148
Hydrogel Bioscaffold and Coating for Bone and Tooth Repair	148
Injectable Composite Material Suitable for Use as a Bone Substitute	148
Bone Filling Complex and Method for Fabricating the Same	149
Composite Material	149
Device for Regeneration of Articular Cartilage and Other Tissue	149
Composition and Method for Self-Assembly and Mineralization of Peptide Amphiphiles	149
Chondroitinase ABC I Polynucleotides	150
Transdiscal Administration of Cycline Compounds	150
Composition and Method for Preparing Biocompatible Surfaces	150
Spinal Mobility Preservation Apparatus Having an Expandable Membrane	151
OSTEOBIOLOGICS AND OSTEOINDUCTIVE GROWTH FACTORS	151
BONE GRAFTS	152
<i>TABLE 23 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL</i>	153
<i>TABLE 24 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION IN THE U.S., THROUGH 2019</i>	154
<i>TABLE 25 BONE GRAFT PROCEDURE VOLUMES BY SOURCE OF GRAFT IN THE U.S., THROUGH 2019</i>	154
<i>TABLE 26 COMPARISON OF BONE GRAFT MATERIALS</i>	155
<i>TABLE 27 TYPES OF SUBSTITUTE BONE GRAFTS</i>	156
AUTOGRAFTS	156
Bioseed Grafts	157
ALLOGRAFTS	158
Demineralized Bone Matrix Products	160
<i>TABLE 28 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX</i>	160
Accell	161
AlphaGRAFT	161
Allomatrix	161
Grafton DBM	161
DBX	161
DynaBlast and DynaGraft-D	161
Graftech	161
Grafton	162

TOPIC	PAGE NO.
Opteform	162
OrthoBlast II	162
Osteofil	163
Xenografts	163
THE MARKET FOR ALLOGRAFTS	163
<i>TABLE 29 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2019 (\$ MILLIONS)</i>	164
CELL-BASED BONE GRAFT SUBSTITUTES	164
FACTOR-BASED BONE GRAFT SUBSTITUTES	165
BONE MORPHOGENIC PROTEINS	166
InductOs	167
INFUSE Bone Graft	167
OP-1 Implant	167
CERAMIC-BASED BONE GRAFT SUBSTITUTES	168
Types of Ceramics	169
Alpha-BSM	170
BioGran	170
Bio-Oss	170
BoneSource	170
Calcigen S	170
Collagraft Strip Bone Graft Matrix	171
Conduit TCP Granules	171
Mimix Bone Substitute Material	171
Norian SRS	171
OsteoGraf	172
Osteoset	172
OsteoStim Resorbable Bone Graft Substitute	172
PerioGlas	172
Pro Osteon Implant	172
Vitoss	173
POLYMER-BASED BONE GRAFT SUBSTITUTES	173
Cortoss	173
Healos	174
Immix Extenders and Immix CB	175
THE MARKET FOR BONE GRAFT PRODUCTS	175
<i>TABLE 30 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	175
<i>TABLE 31 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	175
REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS	176
NANO/MACROPOROUS BONE TISSUE	176
BIOLOGIC/SYNTHETIC GRAFTS	176
CHAPTER 13 WOUND CARE PRODUCTS INCLUDING BIOLOGICAL DRESSINGS	179
WOUND CARE GENERALLY	179
<i>TABLE 32 GLOBAL COMPANIES WITH A SIGNIFICANT FOCUS IN WOUND CARE PRODUCTS</i>	180

TOPIC	PAGE NO.
PRODUCT EFFICACY	182
MARKET SEGMENTS	182
COLLAGEN	182
COLLAGEN IN MEDICAL APPLICATIONS	183
<i>TABLE 33 IDENTIFICATION OF COLLAGEN-BASED PRODUCTS</i>	184
SPECIFIC COLLAGEN PRODUCTS	184
TenoMend Collagen Tendon Wrap	184
CosmoDerm and CosmoPlast Human-Based Collagen	185
TachoSil Fibrin Sealant	185
TISSUE ENGINEERING	186
SKIN SUBSTITUTES: CELLS AND TISSUES	186
ARTIFICIAL SKIN	186
<i>TABLE 34 SKIN SUBSTITUTE PRODUCTS AND THEIR MANUFACTURERS</i>	188
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS	189
<i>TABLE 35 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2019 (\$ MILLIONS)</i>	190
ALGINATES	190
<i>TABLE 36 ALGINATE-BASED PRODUCTS AND THEIR MANUFACTURERS</i>	191
FIBRIN SEALANT PRODUCTS	191
History of Fibrin Sealants	192
CLOTBLOCK - LYOPHILIZED FIBRIN SEALANT	192
FIBRIN MICROTHREADS IN TISSUE REGENERATION	193
PRODUCTS	194
Evicel	194
Artiss	194
ReCell	195
RELATED PRODUCTS: FIRST FDA APPROVED SPINE SEALANT	195
ENZYMATIC DEBRIDING AGENTS	196
<i>TABLE 37 ENZYMATIC DEBRIDING AGENTS AND THEIR MANUFACTURERS</i>	196
NANOSTRUCTURED TEMPERATURE-SENSITIVE MEMBRANES FOR WOUND HEALING AND CELL GRAFTING	197
<i>TABLE 38 MARKETS FOR BIOLOGICAL WOUND CARE PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	197
CHAPTER 14 DRUG-DEVICE COMBINATION PRODUCTS FOR OCULAR APPLICATIONS	199
OVERVIEW	199
FDA APPROVED OPHTHALMIC IMPLANTS	199
<i>TABLE 39 IMPLANTABLE DRUG-DEVICE OPHTHALMOLOGY COMBINATION PRODUCTS APPROVED BY FDA, 2014</i>	200
VITRASERT	200
RETISERT	200
OZURDEX	201
CONTACT LENSES	201
GOOGLE NOVARTIS INITIATIVE IN CONTACT LENSES	202
COMBINATION DRUGS	202
INTRAOCULAR LENS PRODUCTS (IOL)	203
LENS MATERIALS	203
CLEAR LENS EXTRACTION AND REPLACEMENT (CLEAR) SURGERY	204

TOPIC	PAGE NO.
VITREOUS SUBSTITUTES	205
Polymers	205
Perfluorocarbon Liquids (PFCL)	205
Silicone Oil	206
Combination Product: PFCL and Silicone Oil	206
OCULAR DRUG DELIVERY VIA NANOSTRUCTURED DRUG-LOADED CONTACT LENSES	206
MARKET POTENTIAL	208
<i>TABLE 40 MARKETS FOR OCULAR APPLICATIONS IN DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	208
CHAPTER 15 IMPLANTABLES AS DRUG-DEVICE COMBINATIONS	210
OVERVIEW	210
NEUROMODULATION	210
TINNITUS	211
MINIATURE NEUROSTIMULATORS	211
BIODEGRADABLE CIRCUITS	212
BIORESORBABLE DEVICES	213
STEROID ELUTING PACEMAKER LEADS	214
MICROELECTRONIC CONTROL OF DRUG DELIVERY	214
MARKET SIZE	215
<i>TABLE 41 IMPLANTABLE DRUG-DEVICE COMBINATIONS, THROUGH 2019 (\$ MILLIONS)</i>	215
CHAPTER 16 RELATED DRUG-DEVICE COMBINATIONS OF RELEVANCE	217
OVERVIEW	217
MARKET SIZE	217
<i>TABLE 42 MARKETS FOR RELATED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ MILLIONS)</i>	217
<i>INJECTABLE BIODEGRADABLE HYDROGELS FOR DRUG DELIVERY AND TISSUE ENGINEERING</i>	217
SELF-HEALING HYDROGELS	218
HYDROGELS AND MICRO ROBOTS	218
HYDROGEL SCAFFOLDING AT NANO SCALE	219
HYDROGELS AS SMART PILLS	219
IN VIVO FLEXIBLE ELECTRONICS	220
HEAT ACTIVATED DRUGS	220
MEDIFOCUS INC.	221
PHILIPS/CELSION CORP.	221
RADIATION/DRUG COMBINATIONS	223
ANTI-BACTERIAL RELEASING DENTAL RESTORATIVE MATERIALS	224
COMBINATION DENTAL PROPHYLAXIS PASTES AND DRUG COMPONENTS	224
BIOMIMETIC CONTROLLED-RELEASE CAPSULES FOR GUM DISEASE	224
METERED DOSE INHALERS, SPACERS AND OTHER ACCESSORIES	225
ANTIMICROBIAL SUTURES	227
ANTIMICROBIAL VASCULAR GRAFTS	228
BREATH TEST COMBINATION PRODUCTS	229
MYOCELL THERAPY BY BIOHEART INC.	229

TOPIC	PAGE NO.
MICRONEEDLE DRUG AND VACCINE DELIVERY SYSTEMS	231
VACCINE DELIVERY	231
SILK-BASED MICRONEEDLE SYSTEM	232
OPHTHALMIC APPLICATIONS FOR MICRONEEDLES	233
CHAPTER 17 PATENT ANALYSIS	235
PATENT VOLUMES	235
COMPETITIVE ASPECTS	235
INTELLECTUAL PROPERTY ISSUES	236
EXAMPLES OF DRUG-DEVICE COMBINATION PATENTS: 2012 TO 2014	236
THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE	236
MANUAL BASAL BOLUS DRUG DELIVERY DEVICE	236
ASSEMBLY FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE	237
MEDICAL DEVICE WITH DRUG DELIVERY MEMBER	237
DEVICE AND METHOD FOR CREATING AEROSOLS FOR DRUG DELIVERY	238
X-RAY VISIBLE DRUG DELIVERY DEVICE	238
ORAL TRANSMUCOSAL DRUG DELIVERY DEVICE	238
DEVICE AND METHOD FOR DELIVERY OF A DRUG DEPOT NEAR THE NERVE	239
OCULAR DRUG DELIVERY DEVICE	239
APPARATUS AND METHODS FOR LOADING A DRUG ELUTING MEDICAL DEVICE	239
INTRAMEDULLARY DRUG DELIVERY DEVICE AND METHOD OF TREATING BONE FRACTURES	240
METHOD OF FORMING A DRUG-ELUTING MEDICAL DEVICE	240
METHODS TO INCREASE FRACTURE RESISTANCE OF A DRUG-ELUTING MEDICAL DEVICE	240
<i>DRUG ELUTING IMPLANTABLE MEDICAL DEVICE WITH HEMOCOMPATIBLE AND/OR PROHEALING TOPCOAT</i>	241
MEDICAL DEVICE RAPID DRUG RELEASING COATINGS COMPRISING A THERAPEUTIC AGENT AND A CONTRAST AGENT	241
CONTACT LENS DRUG DELIVERY DEVICE	241
<i>DRUG LOADED IMPLANTABLE MEDICAL DEVICE</i>	242
EXAMPLES OF DRUG-DEVICE COMBINATION PATENTS: 2011 TO 2012	242
DRUG-ELUTING STENT AND METHOD OF MAKING THE SAME	242
DERMAL DELIVERY DEVICE WITH REDUCED LOSS OF ITS VOLATILE COMPONENTS	242
METHODS, DEVICES AND FORMULATIONS FOR TARGETED ENDOBRONCHIAL THERAPY	243
DRUG RELEASING COATINGS FOR MEDICAL DEVICES	243
METHOD AND APPARATUS FOR IN SITU DRUG DELIVERY DURING DISTRACTION OSTEOGENESIS	244
DRUG FORMULATIONS FOR COATING MEDICAL DEVICES	244
DRUG DEACTIVATION SYSTEM	244
LIGHT TRANSMISSION SYSTEM FOR PHOTOREACTIVE THERAPY	245
DRUG CONDENSATION AEROSOLS AND KITS	245
<i>IMPLANTABLE DRUG DEPOT FOR WEIGHT CONTROL</i>	246
DEFORMING SURFACE OF DRUG-ELUTING COATING TO ALTER DRUG RELEASE PROFILE OF A MEDICAL DEVICE	246

TOPIC	PAGE NO.
FLUID MANAGEMENT FLOW IMPLANTS OF IMPROVED OCCLUSION RESISTANCE	246
ANTITHROMBOTIC AND ANTI-RESTENOTIC DRUG-ELUTING STENT	247
SWITCH FOR TRANSDERMAL PATCH	247
DRUG-ELUTING BALLOON	247
BIOCOMPATIBLE COATINGS FOR STENTS	248
<i>IMPLANTABLE DRUG DELIVERY DEVICES HAVING ALTERNATING HYDROPHILIC AND AMPHIPHILIC POLYMER LAYERS</i>	248
DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL	248
METHOD FOR INTRAVESICAL DRUG DELIVERY	249
DELIVERY OF ANTIPSYCHOTICS THROUGH AN INHALATION ROUTE	249
NEEDLE-FREE INJECTOR DEVICE WITH AUTOLOADING CAPABILITY	250
OCULAR DRUG DELIVERY DEVICE	250
MICRONEEDLE ARRAY PATCH	250
METHODS OF ADMINISTERING TETRAZOLE-CONTAINING RAPAMYCIN ANALOGS WITH OTHER THERAPEUTIC SUBSTANCES FOR TREATMENT OF VASCULAR DISORDER	251
KINASE INHIBITORS	251
SENSORS HAVING PROTECTIVE ELUTING COATING AND METHOD THEREFOR	252
BIODEGRADABLE DRUG-POLYMER DELIVERY SYSTEM	252
DEVICE AND METHOD FOR TACKING PLAQUE TO A BLOOD VESSEL WALL	252
METHOD FOR LOADING NANOPOROUS LAYERS WITH THERAPEUTIC AGENT	253
STENTS WITH DRUG-ELUTING COATINGS	253
DRUG DELIVERY ENDOVASCULAR GRAFT	254
<i>MEDICATED COATINGS FOR IMPLANTABLE MEDICAL DEVICES INCLUDING POLYACRYLATES</i>	254
COILED WIRE FOR THE CONTROLLED RELEASE OF DRUGS TO THE EYE	254
APPARATUSES AND MEDIA FOR DRUG ELUTION AND METHODS FOR MAKING AND USING THEM	255
TRANSDERMAL PATCH	255
DRUG-ELUTING INTRAVASCULAR PROSTHESES AND METHODS OF USE	255
<i>PROGENITOR ENDOTHELIAL CELL CAPTURING WITH A DRUG-ELUTING IMPLANTABLE MEDICAL DEVICE</i>	256
ONE-STEP PHOSPHORYLCHOLINE-LINKED POLYMER COATING AND DRUG LOADING OF STENT	256
SYSTEMS AND METHODS FOR DELIVERING DRUGS TO SELECTED LOCATIONS WITHIN THE BODY	256
ENDOTRACHEAL TUBE WITH FEATURE FOR DELIVERING AEROSOLIZED MEDICATION	257
METHODS AND SYSTEMS FOR SUBMUCOSAL IMPLANTATION OF A DEVICE FOR DIAGNOSIS AND TREATMENT WITH A THERAPEUTIC AGENT	257
STENTS WITH CERAMIC DRUG RESERVOIR LAYER AND METHODS OF MAKING AND USING THE SAME	258
STENT COATING FOR ELUTING MEDICATION	258
CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS	259
DEVICE FOR CONTROLLED RELEASE OF CHEMICAL MOLECULES	259
<i>DRUG ELUTION FOR IMPLANTABLE INCONTINENCE DEVICES</i>	259

TOPIC	PAGE NO.
DRUG-ELUTING STENT AND DELIVERY SYSTEM WITH TAPERED STENT IN SHOULDER REGION	260
DRUG-ELUTING TISSUE MARKER	260
DELIVERY OF DRUG AMINES THROUGH AN INHALATION ROUTE	260
ENDOPROSTHESIS COATING	261
COGNITIVE FUNCTION WITHIN A HUMAN BRAIN	261
MEDICAL IMPLANT HAVING IMPROVED DRUG-ELUTING FEATURES	261
DELIVERY OF DRUG ESTERS THROUGH AN INHALATION ROUTE	262
ELECTRONICALLY-CONTROLLED DEVICE FOR RELEASE OF DRUGS, PROTEINS, AND OTHER ORGANIC OR INORGANIC CHEMICALS	262
PRELOADING WITH MACULAR PIGMENT TO IMPROVE PHOTODYNAMIC TREATMENT OF RETINAL VASCULAR DISORDERS	262
COATED AND IMPRINTED MEDICAL DEVICES AND METHODS OF MAKING THE SAME	263
METHOD FOR PHOTOTHERMAL THERAPY USING POROUS SILICON AND NEAR INFRARED RADIATION	263
EXAMPLES OF DRUG-DEVICE COMBINATION PATENTS: 2008 TO 2009	263
ELECTROPROCESSED COLLAGEN AND TISSUE ENGINEERING	263
BIOFUNCTIONAL, ANTIMICROBIAL COATINGS FOR MEDICAL DEVICES	264
METHOD AND DEVICE FOR DETECTING AND TREATING DEPRESSION	264
GELATIN DERIVATIVES AND HIGH-MOLECULAR MICELLE COMPRISING THE DERIVATIVES	264
METHODS AND APPARATUS FOR ACUTE OR CHRONIC DELIVERY OF SUBSTANCES OR APPARATUS TO EXTRAVASCULAR TREATMENT SITES	265
WOUND COVERING	265
NANOPARTICLES FOR PROTEIN DRUG DELIVERY	265
PROCESS FOR PROVIDING ANTIMICROBIAL SURFACES	266
GROWTH FACTOR MODIFIED PROTEIN MATRICES FOR TISSUE ENGINEERING	266
<i>METHOD OF COATING IMPLANTABLE MEDICAL DEVICES</i>	266
ANTIMICROBIAL COATING FOR EROSION ENVIRONMENTS	267
METHOD AND COMPOSITION FOR PRODUCING CATHETERS WITH ANTIBACTERIAL PROPERTY	267
<i>IMPLANTABLE MEDICAL DEVICE WITH ANTI-INFECTION AGENT</i>	267
MINIATURE DRUG DELIVERY PUMP WITH A PIEZOELECTRIC DRIVE SYSTEM	268
IONTOPHORESIS DEVICE	268
APPARATUS FOR COATING MEDICAL DEVICES	268
COATINGS FOR DRUG DELIVERY DEVICES	269
THIN-FILM DRUG DELIVERY ARTICLE AND METHOD OF USE	269
IMPLANTABLE, TISSUE CONFORMING DRUG DELIVERY DEVICE	269
<i>IMPLANTABLE DEVICE WITH RESERVOIRS FOR INCREASED DRUG LOADING</i>	270
STENT ASSEMBLY FOR THE TREATMENT OF VULNERABLE PLAQUE	270
APPLICATION OF A THERAPEUTIC SUBSTANCE TO A TISSUE LOCATION USING AN EXPANDABLE MEDICAL DEVICE	270
<i>MULTI-STABLE VALVES FOR MEDICAL APPLICATIONS AND METHODS FOR USE THEREOF</i>	271
METHOD AND APPARATUS FOR DELIVERING COMBINED ELECTRICAL AND DRUG THERAPIES	271
HEPARIN PRODRUGS AND DRUG DELIVERY STENTS FORMED THEREFROM	271
NANOPARTICLE ASSEMBLED HOLLOW SPHERES	272

TOPIC	PAGE NO.
METHOD OF STENT MOUNTING TO FORM A BALLOON CATHETER HAVING IMPROVED RETENTION OF A DRUG DELIVERY STENT	272
STENT HAVING AN ULTRASONIC EMITTER	272
DRUG-ELUTING INTRAVASCULAR PROSTHESES AND METHODS OF USE	273
<i>IMPLANTABLE DRUG DELIVERY DEVICE AND USE THEREOF</i>	273
INTRA-AORTIC RENAL DELIVERY CATHETER	273
SYSTEM AND METHOD FOR DRUG DELIVERY AND MICROFLUIDIC APPLICATIONS USING MICRONEEDLES	274
ENCAPSULATED INORGANIC ANTIMICROBIAL ADDITIVE FOR CONTROLLED RELEASE	274
POLYMER NANOTECHNOLOGY	275
CHAPTER 18 INDUSTRY STRUCTURE AND COMPANY PROFILES	277
OVERVIEW	277
<i>TABLE 43 WORLD'S LARGEST MANUFACTURERS OF MEDICAL DEVICES (\$ BILLIONS)</i>	277
INVESTMENT OVER THE LAST 10 YEARS	278
REVENUES AND PROFITABILITY	279
GLOBAL MARKET COMPETITION	279
COMPANY PROFILES	280
ABBOTT VASCULAR	280
ABL MEDICAL LLC	281
ACRYMED INC.	282
ACTAVIS	283
AFFINERGY INC.	284
AGILE THERAPEUTICS INC.	284
ALCON INC.	285
ALEXZA PHARMACEUTICALS	285
ALLERGAN INC.	286
ALLIED MINDS/BIOTECTIX	286
ANGIOTECH PHARMACEUTICALS INC.	287
ANTARES PHARMA INC.	287
APTALIS PHARMA INC.	288
ARROW INTERNATIONAL	288
AVITA MEDICAL	289
BAXTER INTERNATIONAL INC.	289
BAYER HEALTHCARE	290
BAUSCH & LOMB INC.	291
BEZWADA BIOMEDICAL LLC	291
BIND BIOSCIENCES INC.	292
BIOCOAT INC.	293
BIOCOMPATIBLES U.K. LTD.	294
BIOHEART INC.	295
BIOMET INC.	296
BOSTON SCIENTIFIC CORP.	297
BRONCUS TECHNOLOGIES INC.	297
CAREFUSION CORORATION	298
CELSION CORP.	298
C.R. BARD	299

TOPIC	PAGE NO.
CODMAN & SHURTLEFF INC.	300
COLLAGEN MATRIX INC.	300
COMBINATION PRODUCTS COALITION	301
COOK INC.	301
CORDIS CORP.	302
COVIDIEN, PLC	302
CYNOSURE INC.	303
DELCATH SYSTEMS INC.	303
DEPUY SYNTHES INC. (JOHNSON & JOHNSON)	303
DISCOVERY LABORATORIES INC.	304
DSM BIOMEDICAL HEADQUARTERS	305
DUSA PHARMACEUTICALS INC.	306
EDWARDS LIFESCIENCES CORP.	307
ETEX CORP.	307
EXACTECH INC.	308
GE HEALTHCARE	309
THE HYMED GROUP	309
INFRAREDIX	309
INTEGRA LIFESCIENCES HOLDINGS CORP.	310
INTERPORE CROSS INTERNATIONAL	311
JOHNSON & JOHNSON	312
KALEO INC.	312
KIADIS PHARMA B.V.	313
LIFECELL CORP.	313
LIGHT SCIENCES ONCOLOGY INC.	314
LUTONIX INC.	314
MARTECH MEDICAL PRODUCTS	315
MEDGENICS INC.	315
MEDLINE	316
MEDTRONIC INC.	316
Medtronic Vascular Inc.	316
MERIT MEDICAL SYSTEMS INC.	317
MICROCHIPS INC.	318
MULTIGENE VASCULAR SYSTEMS (MGVS) LTD.	319
MYLAN INC.	319
NOVABONE PRODUCTS LLC	320
NOVARTIS AG	320
OMRIX BIOPHARMACEUTICALS LTD.	321
ORBUSNEICH MEDICAL INC.	321
ORGANOGENESIS INC.	322
PHARMACYCLICS INC.	323
PHOTOCURE ASA	324
PHOTOBOTICS	325
PINNACLE BIOLOGICS	326
PROTEUS DIGITAL HEALTH INC.	326
PSIVIDA CORP	327
PURDUE PHARMA L.P.	328

TOPIC	PAGE NO.
REVA MEDICAL INC.	328
QLT INC.	329
SCIESENT	330
SMITH & NEPHEW, PLC	330
SORIN S.P.A.	331
STANMORE IMPLANTS	331
STRYKER CORP.	332
SURMODICS INC.	333
SYSTAGENIX WOUND MANAGEMENT	334
TEI BIOSCIENCES INC.	334
TERUMO CORP.	335
VALERITAS INC.	336
VISTA SCIENTIFIC LLC	336
WRIGHT MEDICAL GROUP INC.	337
W. L. GORE & ASSOCIATES INC.	337
CHAPTER 19 APPENDIX 1: RECENT FDA APPROVALS OF DEVICES, INCLUDING COMBINATION PRODUCTS	340
OVERVIEW	340
<i>TABLE 44 510(K) PREMARKET NOTIFICATIONS (COMBINATION PRODUCT APPROVALS) BY FDA BETWEEN JULY 2013 AND JULY 2014</i>	340
<i>TABLE 45 510(K) PREMARKET NOTIFICATIONS (COMBINATION PRODUCT APPROVALS) BY FDA BETWEEN AUGUST 2011 AND AUGUST 2012</i>	342
<i>TABLE 46 PRE-MARKET APPROVAL OF COMBINATION PRODUCTS, JULY 2013-JULY 2014</i>	343
<i>TABLE 47 PRE-MARKET APPROVAL OF COMBINATION PRODUCTS, AUGUST 2011-AUGUST 2012</i>	343
<i>TABLE 48 MEDICAL DEVICES APPROVED BY THE FDA IN 2014</i>	344
<i>TABLE 49 MEDICAL DEVICES APPROVED BY THE FDA IN 2013</i>	344
<i>TABLE 50 MEDICAL DEVICES APPROVED BY THE FDA IN 2009</i>	346
<i>TABLE 51 MEDICAL DEVICES APPROVED BY THE FDA IN 2008</i>	346
<i>TABLE 52 MEDICAL DEVICES APPROVED BY THE FDA IN 2007</i>	348
CHAPTER 20 APPENDIX 2: GLOSSARY OF RELEVANT TERMINOLOGY	351

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE SALES OF DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ BILLIONS)	8
TABLE 1 EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS	14
TABLE 2 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS	17
TABLE 3 COMPANIES INVOLVED IN DRUG RELATED NANOTECHNOLOGY R&D OR MANUFACTURING	18
TABLE 4 TRENDS IN COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-2012 (NO. OF PRODUCT SUBMISSIONS)	21
TABLE 5 FDA COMBINATION PRODUCT CATEGORIES, FY2010-FY2012	22
TABLE 6 COMPANIES WITH SIGNIFICANT SPECIALIZATION IN NANOMEDICINE, 2014 (\$ MILLIONS)	34
TABLE 7 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ MILLIONS)	55
TABLE 8 MARKETS FOR CORONARY STENTS, THROUGH 2019 (\$ BILLIONS)	60
TABLE 9 STENT APPROVAL ACTIVITY AT FDA, 2012-2013	64
TABLE 10 EXAMPLES OF STENTS APPROVED FOR CLINICAL USE	69
TABLE 11 RECENT BIOABSORBABLE STENT PATENTS, 2009-2014	70
TABLE 12 PHOTODYNAMIC THERAPY MARKETS, THROUGH 2019 (\$ BILLIONS)	90
TABLE 13 REVENUES ATTRIBUTABLE TO ANTIMICROBIALS THROUGH 2019 (\$ BILLIONS)	97
TABLE 14 REVENUES ATTRIBUTABLE TO MEDICAL DEVICE COATINGS, THROUGH 2019 (\$ BILLIONS)	99
TABLE 15 MEDICAL DEVICE PRODUCTS INCORPORATING AN ANTIMICROBIAL FUNCTION	99
TABLE 16 CURRENT FDA APPROVED CLINICAL TRIALS FOCUSED ON NEW ANTIMICROBIAL CATHETER CONCEPTS (AS OF JULY 2014)	102
TABLE 17 PROJECTED CATHETER MARKET BY PRODUCT TYPE, INCLUDING ANTIMICROBIAL PRODUCTS, THROUGH 2019 (\$ BILLIONS)	105
TABLE 18 CURRENT CLINICAL TRIALS INVOLVING DRUG-ELUTING BEADS	121
TABLE 19 R &D AND REVENUES ATTRIBUTABLE TO DRUG-ELUTED BEADS, THROUGH 2019 (\$ MILLIONS)	129
TABLE 20 ANNUAL SALES OF BONE CEMENTS, INCLUDING COMBINATION PRODUCT ANTIBIOTIC BONE CEMENTS, THROUGH 2019 (\$ MILLIONS)	133
TABLE 21 PRINCIPAL COMPANIES IN THE BONE GRAFT BUSINESS	140
TABLE 22 PATENT ACTIVITY IN BONE GRAFT SUBSTITUTES FROM AUGUST 2010 TO JULY 2014	142
TABLE 23 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL	153
TABLE 24 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION IN THE U.S., THROUGH 2019	154
TABLE 25 BONE GRAFT PROCEDURE VOLUMES BY SOURCE OF GRAFT IN THE U.S., THROUGH 2019	154
TABLE 26 COMPARISON OF BONE GRAFT MATERIALS	155
TABLE 27 TYPES OF SUBSTITUTE BONE GRAFTS	156
TABLE 28 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX	160
TABLE 29 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2019 (\$ MILLIONS)	164
TABLE 30 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2019 (\$ MILLIONS)	175

TABLE HEADING	PAGE NO.
TABLE 31 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2019 (\$ MILLIONS)	175
TABLE 32 GLOBAL COMPANIES WITH A SIGNIFICANT FOCUS IN WOUND CARE PRODUCTS	180
TABLE 33 IDENTIFICATION OF COLLAGEN-BASED PRODUCTS	184
TABLE 34 SKIN SUBSTITUTE PRODUCTS AND THEIR MANUFACTURERS	188
TABLE 35 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2019 (\$ MILLIONS)	190
TABLE 36 ALGINATE-BASED PRODUCTS AND THEIR MANUFACTURERS	191
TABLE 37 ENZYMATIC DEBRIDING AGENTS AND THEIR MANUFACTURERS	196
TABLE 38 MARKETS FOR BIOLOGICAL WOUND CARE PRODUCTS, THROUGH 2019 (\$ MILLIONS)	197
TABLE 39 IMPLANTABLE DRUG-DEVICE OPHTHALMOLOGY COMBINATION PRODUCTS APPROVED BY FDA, 2014	200
TABLE 40 MARKETS FOR OCULAR APPLICATIONS IN DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ MILLIONS)	208
TABLE 41 IMPLANTABLE DRUG-DEVICE COMBINATIONS, THROUGH 2019 (\$ MILLIONS)	215
TABLE 42 MARKETS FOR RELATED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2019 (\$ MILLIONS)	217
TABLE 43 WORLD'S LARGEST MANUFACTURERS OF MEDICAL DEVICES (\$ BILLIONS)	277
TABLE 44 510(K) PREMARKET NOTIFICATIONS (COMBINATION PRODUCT APPROVALS) BY FDA BETWEEN JULY 2013 AND JULY 2014	340
TABLE 45 510(K) PREMARKET NOTIFICATIONS (COMBINATION PRODUCT APPROVALS) BY FDA BETWEEN AUGUST 2011 AND AUGUST 2012	342
TABLE 46 PRE-MARKET APPROVAL OF COMBINATION PRODUCTS, JULY 2013-JULY 2014	343
TABLE 47 PRE-MARKET APPROVAL OF COMBINATION PRODUCTS, AUGUST 2011-AUGUST 2012	343
TABLE 48 MEDICAL DEVICES APPROVED BY THE FDA IN 2014	344
TABLE 49 MEDICAL DEVICES APPROVED BY THE FDA IN 2013	344
TABLE 50 MEDICAL DEVICES APPROVED BY THE FDA IN 2009	346
TABLE 51 MEDICAL DEVICES APPROVED BY THE FDA IN 2008	346
TABLE 52 MEDICAL DEVICES APPROVED BY THE FDA IN 2007	348

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE SALES OF DRUG-DEVICE COMBINATION PRODUCTS, 2013-2019 (\$ BILLIONS)	8